Education
About Us
Working with TipRanks
Follow Us
Bridgebio Pharma (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
$74.27
-$0.10(-0.35%)
At close: 4:00 PM EST
$74.27
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$28.10 - $78.59
Previous CloseN/A
Volume379.31K
Average Volume (3M)1.68M
Market Cap
$14.26B
Enterprise Value$12.03B
Total Cash (Recent Filing)$645.94M
Total Debt (Recent Filing)$1.86B
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding192,708,820
10 Day Avg. Volume1,437,721
30 Day Avg. Volume1,680,346
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)-3.50
Price to Sales (P/S)23.01
P/FCF Ratio-9.79
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue34.01
Enterprise Value/Gross Profit35.51
Enterprise Value/Ebitda-17.77
Forecast
1Y Price Target
$87.53Price Target Upside17.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpsidePositive pivotal Phase 3 results for infigratinib in achondroplasia could establish a new standard of care and unlock a large, high‑value market opportunity for the company.
Commercial TractionRapid and accelerating prescription uptake for Attruby points to expanding revenue potential from both treatment‑naive patients and switches, supporting a stronger commercial outlook for the stock.
Profitability TrajectoryAnalyst projections of a move to positive net income and free cash flow as revenue grows and operating expenses remain controlled could materially improve the company's valuation if achieved.
Bears Say
Addressable Market UncertaintyUncertainty around the true size of the patient population for encaleret in ADH1 raises the risk that peak sales assumptions may be overstated, which could temper upside for the stock if adoption falls short of expectations.
Generic Competition RiskEarlier-than-expected entry of a generic tafamidis or competing silencer combination could constrict Attruby's market share and limit the company's revenue growth potential.
Operating Expense PressureA wider-than-expected net loss driven by elevated selling, general and administrative spending highlights the risk that higher operating costs could delay the path to sustained profitability and increase financing needs.
BridgeBio Pharma News
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $28.10 and its highest was $78.58 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $14.26B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Feb 19, 2026 which is in 42 days.
How were Bridgebio Pharma’s earnings last quarter?
Bridgebio Pharma released its earnings results on Oct 29, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.894 by -$0.056.
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate is -0.72.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 192,708,820 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Bridgebio Pharma reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.894. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Bridgebio Pharma?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.53 (17.85% Upside)
$87.53 (17.85% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.12%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased positive developments with successful Phase III trial results and strong financial performance. However, challenges such as market access competition and increased operating expenses were noted.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$87.53
▲(17.85% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
20.82% Insiders
21.32% Mutual Funds
42.59% Other Institutional Investors
0.36% Public Companies and Individual Investors